...
首页> 外文期刊>Case Reports in Oncology >Immunocytochemistry Test of Protein BRAF Expression for Diagnosis of Well Differentiated Thyroid Carcinoma
【24h】

Immunocytochemistry Test of Protein BRAF Expression for Diagnosis of Well Differentiated Thyroid Carcinoma

机译:蛋白质BRAF表达的免疫细胞化学测试可用于高度分化的甲状腺癌的诊断

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background: Thyroid carcinoma generally has a good prognosis. The main focus of current research on thyroid carcinoma is to increase the accuracy of preoperative diagnosis of thyroid nodules. When the result of fine needle aspiration biopsy (FNAB) is indeterminate, clinicians often have doubts in determining the surgical management. Objective: Protein BRAF expression analysis can help improve the accuracy of FNAB and optimize the management of differentiated thyroid carcinoma. Methods: This study is a diagnostic test performed from October 2016 at Sanglah General Hospital with 38 patients as subjects who fulfilled the inclusion criteria. Data is being presented in descriptive form before diagnostic test is done to determine sensitivity, specificity, positive predictive value, negative predictive value and the accuracy of immunocytochemistry test for BRAF on indeterminate thyroid nodule. Results: Thirty-eight samples met the inclusion criteria during the study period. Three samples were male (7.9%) and 35 samples (92.1%) were female. The mean age of the sample was 45.21 years (SD ±10.910 years) with ages ranging from 23 to 66 years. Of the 12 samples undergoing isthmolobectomy, 7 samples (58.4%) were determined to be malignant from histopathological results. The sensitivity value of BRAF immunocytochemistry test is 45.45% with a specificity value of 81.25%, a positive predictive value of 76.92%, a negative predictive value of 52% and an accuracy of 60.50%. Analysis of the receiver operator (ROC) curve shows the area under the curve (AUC) of 63.4% with a confidence interval of 45.5–81.2%. Conclusion: Immunocytochemistry BRAF test have a reliable diagnostic value and can be taken into consideration in the preoperative diagnosis of thyroid malignancies.
机译:背景:甲状腺癌一般预后良好。当前关于甲状腺癌的研究的主要焦点是提高甲状腺结节的术前诊断的准确性。当细针穿刺活检(FNAB)的结果不确定时,临床医生通常会在确定手术管理方法时产生疑问。目的:蛋白BRAF表达分析有助于提高FNAB的准确性,优化分化型甲状腺癌的治疗。方法:这项研究是自2016年10月起在桑格拉总医院进行的一项诊断测试,其中38例患者符合纳入标准。在进行诊断测试之前,将以描述性形式提供数据,以确定不确定的甲状腺结节是否适用于BRAF的敏感性,特异性,阳性预测值,阴性预测值和免疫细胞化学测试的准确性。结果:38个样本在研究期间符合纳入标准。男性为三个样本(7.9%),女性为35个样本(92.1%)。样本的平均年龄为45.21岁(SD±10.910岁),年龄范围为23至66岁。从组织病理学结果中,在接受了肺叶切除术的12个样本中,有7个样本(58.4%)被确定为恶性。 BRAF免疫细胞化学检测的敏感性值为45.45%,特异性值为81.25%,阳性预测值为76.92%,阴性预测值为52%,准确度为60.50%。接收机操作员(ROC)曲线的分析显示,曲线下的面积(AUC)为63.4%,置信区间为45.5-81.2%。结论:免疫细胞化学BRAF检测具有可靠的诊断价值,可在甲状腺恶性肿瘤的术前诊断中予以考虑。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号